| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Regulation FD Disclosure
Members of the senior management team of Molina Healthcare, Inc. (“Molina” or the “Company”) will be participating in UBS’s Global Healthcare Conference on Monday, November 9, 2026. During the conference, and in discussions with investor... |
| 21 Oct 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 22 Jul 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 10 Jun 2026 |
8-K: Regulation FD Disclosure
Investor Contact: Jeff Geyer, [email protected], 305-317-3012 |
| 11 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
#2008106v1 AMENDED AND RESTATED BYLAWS OF MOLINA HEALTHCARE, INC. a Delaware corporation (as Amended and Restated Effective May 6, 2026) |
| 08 May 2026 |
8-K: Regulation FD Disclosure
As previously announced, Molina Healthcare, Inc. (the “Company”) will host its Investor Day Conference on May 8, 2026, beginning at 9:30 a.m. Eastern Time. At the event, the Company will provide various updates regarding its business, in... |
| 22 Apr 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
Members of the senior management team of Molina Healthcare, Inc. (“Molina” or the “Company”) will be meeting with investors and analysts over the next several days, and on Tuesday, March 3, 2026, will also be participating in TD Cowen’s ... |
| 06 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
THIS FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of February 4, 2026 (this “Amendment”), is entered into between Molina Healthcare, Inc., a Delaware corporation (the “Borrower”), each of the Lenders party hereto constituting Required L... |
| 05 Feb 2026 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 20 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
THIS CREDIT AGREEMENT (this “Agreement”) is made and entered into as of November 20, 2025, by and among MOLINA HEALTHCARE, INC., a Delaware corporation (the “Borrower”), the Lenders (defined herein), and TRUIST BANK, in its capacity as a... |
| 18 Nov 2025 |
8-K: Regulation FD Disclosure
Investor Contact: Jeff Geyer, [email protected], 305-317-3012 |
| 17 Nov 2025 |
8-K: Regulation FD Disclosure
Investor Contact: Jeff Geyer, [email protected], 305-317-3012 |
| 14 Nov 2025 |
8-K: Regulation FD Disclosure
Investor Contact: Jeff Geyer, [email protected], 305-317-3012 |
| 22 Oct 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 12 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS FOURTH AMENDMENT TO CREDIT AGREEMENT, dated as of August 12, 2025 (this “Amendment”), is entered into between Molina Healthcare, Inc., a Delaware corporation (the “Borrower”), each of the Lenders party hereto, and Truist Bank, in it... |
| 23 Jul 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 07 Jul 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
| 01 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1.1 Establishment. Molina Healthcare, Inc. previously adopted the Molina Healthcare, Inc. 2019 Equity Incentive Plan (the “2019 Plan”). The 2019 Plan is hereby amended, restated, and merged into the Molina Healthcare, Inc. 2025 Equity In... |
| 23 Apr 2025 |
8-K: Results of Operations and Financial Condition
Investor Contact: Jeffrey Geyer, [email protected], 305-317-3012 |
Loading...